Novel blood-based biomarkers for dementia could identify disease at an early preclinical stage, serve as surrogate outcomes for clinical trials of investigational therapies and even identify future potential therapeutic targets. Unlike cerebrospinal fluid bio…

Read More

Drop your comments

Click to Comment

Share this post with your friends on


COMMENTS (0)

Reply

All fields are required

Save my name for the next time I comment